Invivyd, Inc.
NASDAQ:IVVDBiotechnology
+$0.04 today
- Market cap
- $138.68M
- Beta
- 0.63
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$0.25
Volume 6.71M
Average 3.62M
IVVD Total Current Liabilities
All obligations due within one year.
Invivyd, Inc.NASDAQ: IVVD
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 36.2% from a year ago
Total current liabilities stood at $31.66M at the end of Q1 FY2026, down 36.2% from a year earlier and down 7.3% from the prior quarter. Over 3 fiscal years it compounded at +10.9% a year.
Context
- Total current liabilities amounted to 13.1% of total assets at the end of Q1 FY2026, down 34.7 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -36.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 34.16M USD
- Year-over-year change
- -44.9%
- 4-year CAGR
- -13.9%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.16M | -44.9% |
| FY2024 | 2024-12-31 | 61.98M | +23.2% |
| FY2023 | 2023-12-31 | 50.29M | +100.9% |
| FY2022 | 2022-12-31 | 25.03M | -59.7% |
| FY2021 | 2021-12-31 | 62.06M | — |
Total Current Liabilities vs competitors
How IVVD compares with its peers on the latest reported figures
- IVVD's Mar 2026 total current liabilities of $31.66M is the 2nd highest of the 10 companies compared; the peer median is $13.69M.
- Its year-over-year change of -36.2% is the lowest of 10, against a peer median of +7.2%.
- Total current liabilities amounts to 13.1% of total assets for IVVD, versus a peer median of 11.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $53.13M | +7.2% | -27.6% | 88.6% | |
| Mar 2026 | $31.66M | -36.2% | +10.9% | 13.1% | |
| Mar 2026 | $27.25M | -33.2% | -9.5% | 8.3% | |
| Mar 2026 | $16.29M | -9.8% | — | 489.1% | |
| Mar 2026 | $14.85M | -29.0% | -19.8% | 11.5% | |
| Mar 2026 | $13.69M | -11.6% | -3.4% | 13.6% | |
| Mar 2026 | $13.57M | +18.9% | -14.5% | 4.6% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | $12.01M | +24.0% | -0.1% | 29.7% |
| Sep 2026 | $9.29M | +56.7% | -23.2% | 6.6% | |
| Mar 2026 | $8.92M | +27.1% | +24.0% | 4.6% | |
| Peer median (excluding IVVD) | $13.69M | +7.2% | -12.0% | 11.5% | |
Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 542.22M | 92.08M | 200.64M | 69.35M | 226.69M |
| Short-term Investments | 49.19M | 279.92M | 0 | 0 | 0 |
| Net Receivables | 229K | 377K | 933K | 11.17M | 14.6M |
| Inventory | 0 | 0 | 0 | 0 | 25.5M |
| Other Current Assets | 0 | 0 | 0 | 0 | (23.78M) |
| Total Current Assets | 616.71M | 376.92M | 224.88M | 100.68M | 247.47M |
| Property, Plant & Equipment (Net) | 83K | 6.06M | 4.13M | 2.89M | 3.81M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.3M | 191K | 175K | 25.94M | 25.61M |
| Total Non-current Assets | 3.38M | 6.25M | 4.3M | 28.83M | 29.42M |
| Total Assets | 620.09M | 383.17M | 229.18M | 129.52M | 276.88M |
| Account Payables | 5.78M | 1.52M | 7.95M | 10.45M | 13.74M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.95M | 6.03M | 10.79M | 3.94M | 5.8M |
| Total Current Liabilities | 62.06M | 25.03M | 50.29M | 61.98M | 34.16M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 12K | 1K | 700K | 0 | 0 |
| Total Non-current Liabilities | 12K | 2.17M | 1.42M | (1) | 1.18M |
| Total Liabilities | 62.07M | 27.2M | 51.71M | 61.98M | 35.34M |
| Common Stock | 11K | 11K | 11K | 12K | 28K |
| Retained Earnings | (292.11M) | (533.43M) | (732.07M) | (901.99M) | (954.48M) |
| Accumulated OCI | (8K) | (272K) | (13K) | (5K) | (41K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 558.02M | 355.97M | 177.47M | 67.54M | 241.54M |
| Total Debt | 0 | 3.72M | 2.17M | 1.3M | 2.49M |
| Net Debt | (542.22M) | (88.35M) | (198.48M) | (68.05M) | (224.2M) |
Invivyd, Inc.
NASDAQ:IVVD
Intrinsic Alpha fair value
Locked
Current Price
$0.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.